Drugs Withdrawn from Costa Rican Market

The Ministry of Health decided to withdraw all registered drugs containing oral ranitidine from the market, arguing that long-term exposure of people to this substance may increase the risk of cancer.

Wednesday, October 9, 2019

With the available data there is no evidence that the presence of this substance could have caused harm to patients who have consumed the drug, however, the potential risk arising from the cumulative effect, makes it necessary for health regulatory authorities to take different precautionary measures to avoid their presence in medicines, informed local authorities.

You may be interested in “Participants in the Costa Rican pharmaceutical market

From the Ministry of Health statement:

October 07, 2019. The Ministry of Health, through the Direction of Regulation of Products of Sanitary Interest and following the alerts and informative notes published by different International Regulatory Authorities, communicates to health professionals and the general population about the detection of N-Nitroso dimethylamine (NDMA) in the analysis carried out in several batches of medicines containing the active principle ranitidine.

On the drug RANITIDINE:
Ranitidine is a drug used to reduce acid production in the stomach in situations such as gastric ulcer or gastroesophageal reflux.

Read full statement (In Spanish).

¿Busca soluciones de inteligencia comercial para su empresa?

Do you need more information about your business sector?

Request more information:

this site is protected by reCAPTCHA and Google's privacy policy and terms of service.
Need assistance? Contact us
(506) 4001-6423

More on this topic

Medicines: Changes Approved in Panamanian Market

October 2019

In the third debate, the Assembly approved a bill establishing that the government may make exceptions to the sanitary registration of pharmaceutical products in situations of critical shortage.

At the same time, it empowers the Ministry of Health to purchase medicines under the criteria established by the World Health Organization (WHO), which will allow that when local agents do not participate in the sale, it will be possible to go through international agents, informed the National Assembly on October 3.

Medications: Changes Proposed in Panama

August 2019

The most important change proposed by the authorities is to make exceptions to the health registration of pharmaceutical products in situations of critical shortage.

After receiving the approval from the Cabinet Council, it is expected that next week, the Minister of Health, Rosario Turner Montenegro, will present before the National Assembly the Draft Law, which seeks to amend Law 1 on Medicines.

Perspectives for the Pharmaceutical Sector

August 2018

In El Salvador, companies in the pharmaceutical industry plan to achieve 5% growth in exports of their products this year.

A rebound in sales to Honduras and the opening of new markets is what is behind the projection of growth that the Association of Chemical-Pharmaceutical Manufacturers of El Salvador (INQUIFAR) has for this year.

Panama: New Law on Controlled Drugs

March 2016

A law has been approved that regulates activities on use of controlled substances and drugs and streamlines their import, manufacture, and marketing.

From a statement issued by the National Assembly of Panama:

The full National Assembly approved regulating activities on the use of controlled substances for medical and scientific purposes, in order to facilitate access to medicines which are appropriate for use against chronic and terminal ailments.